Business Context and Reporting Period
This Form 8-K Current Report was filed by Enochian Biosciences Inc. (not Lunai Bioworks Inc.) on June 2, 2022, covering the event date of June 1, 2022. The registrant is a Delaware corporation with its principal executive offices in North Hollywood, CA. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol ENOB.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate event rather than a financial statement release.
Material Changes
The material event reported is the publication of a letter to shareholders on the company's website on June 1, 2022. The content of this letter is furnished as Exhibit 99.1. The filing explicitly states that the information in Item 8.01 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the Shareholder Letter (Exhibit 99.1), which is referenced but not included in the provided text.
Key Facts for Investor Verification
- Verify the content of the Shareholder Letter (Exhibit 99.1) to understand the specific message communicated to investors on June 1, 2022.
- Confirm that the company name is Enochian Biosciences Inc. (ENOB), as the input metadata referenced "Lunai Bioworks Inc."
- Note that the information in this 8-K is not incorporated by reference into other SEC filings.
- Check the company's website for the full text of the shareholder letter referenced in Item 8.01.